108 related articles for article (PubMed ID: 2526211)
41. The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice.
Rodgers DT; McGrath MA; Pineda MA; Al-Riyami L; Rzepecka J; Lumb F; Harnett W; Harnett MM
Arthritis Rheumatol; 2015 Apr; 67(4):1023-35. PubMed ID: 25546822
[TBL] [Abstract][Full Text] [Related]
42. Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice.
Jabs DA; Lee B; Burek CL; Saboori AM; Prendergast RA
Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):377-83. PubMed ID: 8603842
[TBL] [Abstract][Full Text] [Related]
43. Nephritogenicity of the lprcg gene on the MRL background.
Kimura M; Ogata Y; Shimada K; Wakabayashi T; Onoda H; Katagiri T; Matsuzawa A
Immunology; 1992 Jul; 76(3):498-504. PubMed ID: 1526655
[TBL] [Abstract][Full Text] [Related]
44. CD47 deficiency ameliorates autoimmune nephritis in Fas(lpr) mice by suppressing IgG autoantibody production.
Shi L; Bian Z; Chen CX; Guo YN; Lv Z; Zeng C; Liu Z; Zen K; Liu Y
J Pathol; 2015 Nov; 237(3):285-95. PubMed ID: 26095930
[TBL] [Abstract][Full Text] [Related]
45. Effect of cyclophosphamide on leukocytic infiltration in the brain of MRL/lpr mice.
Farrell M; Sakić B; Szechtman H; Denburg JA
Lupus; 1997; 6(3):268-74. PubMed ID: 9104735
[TBL] [Abstract][Full Text] [Related]
46. Induction of various autoantibodies by mutant gene lpr in several strains of mice.
Izui S; Kelley VE; Masuda K; Yoshida H; Roths JB; Murphy ED
J Immunol; 1984 Jul; 133(1):227-33. PubMed ID: 6609979
[TBL] [Abstract][Full Text] [Related]
47. Pathogenesis of lupus dermatoses in autoimmune mice. XIX. Attempts to induce subepidermal immunoglobulin deposition in MRL/Mp- +/+ mice.
Furukawa F; Ohshio G; Imamura S
Arch Dermatol Res; 1993; 285(1-2):20-6. PubMed ID: 8470930
[TBL] [Abstract][Full Text] [Related]
48. IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice.
Hagiwara E; Okubo T; Aoki I; Ohno S; Tsuji T; Ihata A; Ueda A; Shirai A; Okuda K; Miyazaki J; Ishigatsubo Y
Cytokine; 2000 Jul; 12(7):1035-41. PubMed ID: 10880249
[TBL] [Abstract][Full Text] [Related]
49. Immunoglobulin and autoantibody responses in MRL/lpr mice treated with 'toxic oils'.
Koller LD; Stang BV; Hall JA; Posada de la Paz M; Ruiz Mendez MV
Toxicology; 2002 Sep; 178(2):119-33. PubMed ID: 12160619
[TBL] [Abstract][Full Text] [Related]
50. A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice.
Komori H; Furukawa H; Mori S; Ito MR; Terada M; Zhang MC; Ishii N; Sakuma N; Nose M; Ono M
J Immunol; 2006 Jan; 176(1):395-400. PubMed ID: 16365433
[TBL] [Abstract][Full Text] [Related]
51. Prevention of autoimmune hearing loss in MRL/lpr mice by bone marrow transplantation.
Lee S; Iwai H; Sugiura K; Takeuchi K; Kushida T; Tomoda K; Inaba M; Yamashita T; Ikehara S
Bone Marrow Transplant; 2000 Oct; 26(8):887-92. PubMed ID: 11081390
[TBL] [Abstract][Full Text] [Related]
52. Arteritis in a novel congenic strain of mice derived from MRL/Lpr lupus mice: genetic dissociation from glomerulonephritis and limited autoantibody production.
Nose M; Nishimura M; Ito MR; Toh J; Shibata T; Sugisaki T
Am J Pathol; 1996 Nov; 149(5):1763-9. PubMed ID: 8909264
[TBL] [Abstract][Full Text] [Related]
53. The genetics of autoantibody production in MRL/lpr lupus mice.
Eisenberg RA; Craven SY; Fisher CL; Morris SC; Rapoport R; Pisetsky DS; Cohen PL
Clin Exp Rheumatol; 1989; 7 Suppl 3():S35-40. PubMed ID: 2514059
[TBL] [Abstract][Full Text] [Related]
54. Immune complex-degradation ability of macrophages in MRL/Mp-lpr/lpr lupus mice and its regulation by cytokines.
Kanno H; Tachiwaki O; Nose M; Kyogoku M
Clin Exp Immunol; 1994 Jan; 95(1):115-21. PubMed ID: 8287594
[TBL] [Abstract][Full Text] [Related]
55. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis.
Takahashi S; Nose M; Sasaki J; Yamamoto T; Kyogoku M
J Immunol; 1991 Jul; 147(2):515-9. PubMed ID: 2071894
[TBL] [Abstract][Full Text] [Related]
56. Type I IFN protects against murine lupus.
Hron JD; Peng SL
J Immunol; 2004 Aug; 173(3):2134-42. PubMed ID: 15265950
[TBL] [Abstract][Full Text] [Related]
57. Anti-P autoantibody production requires P1/P2 as immunogens but is not driven by exogenous self-antigen in MRL mice.
Hines JJ; Weissbach H; Brot N; Elkon K
J Immunol; 1991 May; 146(10):3386-95. PubMed ID: 2026870
[TBL] [Abstract][Full Text] [Related]
58. Combined treatment of autoimmune MRL/MP-lpr/lpr mice with a herbal medicine, Ren-shen-yang-rong-tang (Japanese name: Ninjin-youei-to) plus suboptimal dosage of prednisolone.
Zhou NN; Nakai S; Kawakita T; Oka M; Nagasawa H; Himeno K; Nomoto K
Int J Immunopharmacol; 1994 Oct; 16(10):845-54. PubMed ID: 7843856
[TBL] [Abstract][Full Text] [Related]
59. Ocular inflammation in autoimmune MRL/Mp mice.
Jabs DA; Alexander EL; Green WR
Invest Ophthalmol Vis Sci; 1985 Sep; 26(9):1223-9. PubMed ID: 4030250
[TBL] [Abstract][Full Text] [Related]
60. Involvement in lupus disease of idiotypes Id.F-423 and Id.IV-228 defined, respectively, upon foetal and adult MRL/Mp-lpr/lpr DNA-binding monoclonal autoantibodies.
Ravirajan CT; Staines NA
Immunology; 1991 Oct; 74(2):342-7. PubMed ID: 1748483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
